Literature DB >> 30412195

The Reporting Items for Patent Landscapes statement.

James A Smith1,2, Zeeshaan Arshad2,3, Anthony Trippe4, Gary S Collins1,5, David A Brindley2,6,7,8,9, Andrew J Carr1,5.   

Abstract

The reporting quality of patent landscapes is inadequate. The Reporting Items for Patent Landscapes (RIPL) checklist can improve reporting quality.

Mesh：

Year:  2018        PMID： 30412195     DOI： 10.1038/nbt.4291

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


  24 in total

1.  Non-CFC metered dose inhalers: the patent landscape.

Authors:  P A Bowman; D Greenleaf
Journal:  Int J Pharm       Date:  1999-09-10       Impact factor: 5.875

2.  The quality of reporting in published cost-utility analyses, 1976-1997.

Authors:  P J Neumann; P W Stone; R H Chapman; E A Sandberg; C M Bell
Journal:  Ann Intern Med       Date:  2000-06-20       Impact factor: 25.391

3.  Minimum information about a microarray experiment (MIAME)-toward standards for microarray data.

Authors:  A Brazma; P Hingamp; J Quackenbush; G Sherlock; P Spellman; C Stoeckert; J Aach; W Ansorge; C A Ball; H C Causton; T Gaasterland; P Glenisson; F C Holstege; I F Kim; V Markowitz; J C Matese; H Parkinson; A Robinson; U Sarkans; S Schulze-Kremer; J Stewart; R Taylor; J Vilo; M Vingron
Journal:  Nat Genet       Date:  2001-12       Impact factor: 38.330

Review 4.  Describing reporting guidelines for health research: a systematic review.

Authors:  David Moher; Laura Weeks; Mary Ocampo; Dugald Seely; Margaret Sampson; Douglas G Altman; Kenneth F Schulz; Donald Miller; Iveta Simera; Jeremy Grimshaw; John Hoey
Journal:  J Clin Epidemiol       Date:  2011-01-08       Impact factor: 6.437

5.  Epidemiology and reporting of randomised trials published in PubMed journals.

Authors:  An-Wen Chan; Douglas G Altman
Journal:  Lancet       Date:  2005 Mar 26-Apr 1       Impact factor: 79.321

6.  What is missing from descriptions of treatment in trials and reviews?

Authors:  Paul Glasziou; Emma Meats; Carl Heneghan; Sasha Shepperd
Journal:  BMJ       Date:  2008-06-28

7.  Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force.

Authors:  Don Husereau; Michael Drummond; Stavros Petrou; Chris Carswell; David Moher; Dan Greenberg; Federico Augustovski; Andrew H Briggs; Josephine Mauskopf; Elizabeth Loder
Journal:  Value Health       Date:  2013 Mar-Apr       Impact factor: 5.725

8.  Epidemiology and reporting characteristics of systematic reviews.

Authors:  David Moher; Jennifer Tetzlaff; Andrea C Tricco; Margaret Sampson; Douglas G Altman
Journal:  PLoS Med       Date:  2007-03-27       Impact factor: 11.069

9.  Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement.

Authors:  David Moher; Larissa Shamseer; Mike Clarke; Davina Ghersi; Alessandro Liberati; Mark Petticrew; Paul Shekelle; Lesley A Stewart
Journal:  Syst Rev       Date:  2015-01-01

Review 10.  Can literature analysis identify innovation drivers in drug discovery?

Authors:  Pankaj Agarwal; David B Searls
Journal:  Nat Rev Drug Discov       Date:  2009-11       Impact factor: 84.694
View more
  5 in total

1.  European patent protection for medical uses of known products and drug repurposing.

Authors:  Mateo Aboy; Kathleen Liddell; Matthew Jordan; Cristina Crespo; Johnathon Liddicoat
Journal:  Nat Biotechnol       Date:  2022-04       Impact factor: 54.908

2.  What, Where, When and How of COVID-19 Patents Landscape: A Bibliometrics Review.

Authors:  Kunmeng Liu; Xiaoming Zhang; Yuanjia Hu; Weijie Chen; Xiangjun Kong; Peifen Yao; Jinyu Cong; Huali Zuo; Jian Wang; Xiang Li; Benzheng Wei
Journal:  Front Med (Lausanne)       Date:  2022-07-01

3.  Global research on artemisinin and its derivatives: Perspectives from patents.

Authors:  Kunmeng Liu; Huali Zuo; Guoguo Li; Hua Yu; Yuanjia Hu
Journal:  Pharmacol Res       Date:  2020-06-23       Impact factor: 7.658

Review 4.  Global landscape of patents related to human coronaviruses.

Authors:  Kunmeng Liu; Zixuan Gu; Md Sahidul Islam; Thomas Scherngell; Xiangjun Kong; Jing Zhao; Xin Chen; Yuanjia Hu
Journal:  Int J Biol Sci       Date:  2021-04-10       Impact factor: 6.580

5.  Delivery of therapeutic small interfering RNA: The current patent-based landscape.

Authors:  Yu Chen; Shi-Hang Xiong; Fei Li; Xiang-Jun Kong; De-Fang Ouyang; Ying Zheng; Hua Yu; Yuan-Jia Hu
Journal:  Mol Ther Nucleic Acids       Date:  2022-06-22       Impact factor: 10.183
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.